Current oncologyPub Date : 2026-10-21DOI: 10.3390/curroncol33100639
Taliha Güçlü Kantar, Tolga Doğan, Burcu Yapar Taşköylü, Atike Gökçen Demiray, Arzu Yaren, Tarık Şengöz, Gamze Gököz Doğu
{"title":"Skeletal Muscle Index and Baseline Biomarkers in Atezolizumab-Treated Extensive-Stage Small-Cell Lung Cancer: A Real-World Cohort Study.","authors":"Taliha Güçlü Kantar, Tolga Doğan, Burcu Yapar Taşköylü, Atike Gökçen Demiray, Arzu Yaren, Tarık Şengöz, Gamze Gököz Doğu","doi":"10.3390/curroncol33100639","DOIUrl":"10.3390/curroncol33100639","url":null,"abstract":"<p><p>Body composition and routinely available blood biomarkers may help characterize prognosis in extensive-stage small-cell lung cancer (ES-SCLC). We retrospectively evaluated 81 patients who received first-line carboplatin, etoposide, and atezolizumab. Baseline L3 skeletal muscle index (SMI) was derived from [18F]FDG PET/CT and classified using the Martin criteria. Overall survival (OS) was assessed using Kaplan-Meier and Cox regression. Of 80 classifiable patients, 33 (41.3%) had low SMI. Median OS was 10.51 months (95% CI, 7.98-14.26) and was 8.48 versus 14.26 months in patients with low versus normal SMI (log-rank <i>p</i> = 0.050). In the primary multivariable model, low SMI was associated with higher mortality (HR, 2.03; 95% CI, 1.07-3.86; <i>p</i> = 0.030); lower albumin and higher lactate dehydrogenase were also associated with mortality. In exploratory analyses, the low-SMI association persisted after post hoc adjustment for bone metastasis (HR, 2.16; 95% CI, 1.05-4.42; <i>p</i> = 0.035), although diagnostics suggested time-varying effects. Continuous SMI and alternative thresholds were not associated with OS, and low SMI was not associated with progression-free survival. Martin-defined low SMI may complement routine biomarkers in prognostic assessment, but its cutoff- and time-dependent association requires cautious interpretation and external evaluation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-21DOI: 10.3390/curroncol33100640
Andrei Popescu, Mara Jidveian-Popescu, Beatrice Mahler, Rodica Olteanu, Emanuel Clem
{"title":"AI-Generated Treatment Recommendations in Newly Diagnosed Lung Cancer: A Single-Center Feasibility Study in a Resource-Limited Setting.","authors":"Andrei Popescu, Mara Jidveian-Popescu, Beatrice Mahler, Rodica Olteanu, Emanuel Clem","doi":"10.3390/curroncol33100640","DOIUrl":"10.3390/curroncol33100640","url":null,"abstract":"<p><strong>Background: </strong>How treatment recommendations generated by large language models (LLMs) compare with real-world decisions in oncology remains poorly characterized, particularly in resource-limited settings.</p><p><strong>Methods: </strong>In this single-center feasibility study, four LLMs (ChatGPT, Claude, Gemini, and Grok, accessed via consumer interfaces in June 2026) generated treatment recommendations for 27 consecutive newly diagnosed lung cancer cases treated at a Romanian oncology unit (June 2024-May 2026). Each model's output and the treatment actually delivered were formatted identically (135 recommendations total), presented in randomized order, and scored for appropriateness (1-5) by a reviewer blinded to the source, with three quality flags. A second independent reviewer re-scored all recommendations to assess inter-rater reliability. Scores were compared using the Friedman test.</p><p><strong>Results: </strong>Mean appropriateness was highest for the real-world decision (4.52), followed by ChatGPT (4.48), Claude (4.44), Grok (4.41), and Gemini (4.37), with no significant difference (Friedman χ<sup>2</sup><sub>4</sub> = 1.99, <i>p</i> = 0.74). No recommendation scored below 3. Inter-rater agreement was high in raw terms (93.3% within one point) but only fair after chance correction (weighted κ = 0.26), reflecting a ceiling effect.</p><p><strong>Conclusions: </strong>AI-generated recommendations were rated similarly to real-world decisions. The evaluation method proved feasible in a resource-limited setting; the small sample and ceiling effect preclude equivalence claims, and the findings are hypothesis-generating.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-21DOI: 10.3390/curroncol33100638
Bulent Yildiz, Yasemin Sagdic Karateke, Duygu Bayir Garbioglu, Metin Demir
{"title":"Association Between the Number of Invasive Tumor Foci and Axillary Nodal Burden in Multifocal and Multicentric Breast Cancer.","authors":"Bulent Yildiz, Yasemin Sagdic Karateke, Duygu Bayir Garbioglu, Metin Demir","doi":"10.3390/curroncol33100638","DOIUrl":"10.3390/curroncol33100638","url":null,"abstract":"<p><p>Multifocal and multicentric (MF/MC) breast cancers are associated with increased axillary lymph node involvement, but the relevance of the number of invasive tumor foci is less clear. This retrospective study included 1087 patients with non-metastatic invasive breast cancer who underwent definitive surgery between 2010 and 2022 without prior neoadjuvant therapy. Patients were grouped as having one, two, or three or more invasive foci; the three-or-more-foci category was used pragmatically to avoid small subgroups at higher focus counts rather than as a data-derived threshold. Multivariable logistic and Cox regression analyses were used to evaluate advanced nodal disease (N2/N3) and disease-free survival (DFS), respectively. N2/N3 disease was present in 18.4%, 19.0%, and 38.2% of patients, respectively (<i>p</i> < 0.001). Three or more foci were independently associated with N2/N3 disease (OR 2.81, 95% CI 1.65-4.79; <i>p</i> < 0.001), whereas two foci were not. At a median follow-up of 113.1 months, 10-year DFS rates were 77.0%, 82.5%, and 55.7%, respectively (log-rank <i>p</i> = 0.003). Three or more foci remained associated with poorer DFS after multivariable adjustment (HR 1.58, 95% CI 1.07-2.33; <i>p</i> = 0.022), whereas two foci were not. A statistically significant difference in OS was not demonstrated (log-rank <i>p</i> = 0.088), although the study may have had limited power for this endpoint. Greater nodal burden and poorer DFS were mainly observed in patients with three or more invasive foci. Focus number may help characterize this heterogeneity within MF/MC disease, although its value beyond total invasive tumor burden remains uncertain.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-21DOI: 10.3390/curroncol33100641
Maan Awad, Sunanda Tah, Syed Ahmad, Het Patel, Prajwal Kumsi Sreedhar, Shanmukh Sai Pavan Lingamsetty, Abdulrahman Murshid, Brijesh Patel
{"title":"Comparative Cardiovascular Outcomes in Acalabrutinib vs. Zanubrutinib in B-Cell Malignancies: A TriNetX Data Study.","authors":"Maan Awad, Sunanda Tah, Syed Ahmad, Het Patel, Prajwal Kumsi Sreedhar, Shanmukh Sai Pavan Lingamsetty, Abdulrahman Murshid, Brijesh Patel","doi":"10.3390/curroncol33100641","DOIUrl":"10.3390/curroncol33100641","url":null,"abstract":"<p><p>Next-generation Bruton's tyrosine kinase inhibitors (BTKis) such as acalabrutinib and zanubrutinib have improved treatment outcomes in B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM), while reducing off-target toxicities compared to ibrutinib. However, their comparative cardiovascular safety profiles remain poorly characterized. This study evaluates real-world cardiovascular and clinical outcomes between zanubrutinib and acalabrutinib using a large multi-center database. We conducted a retrospective cohort study using the TriNetX Research Network (October 2017-December 2024) including adult patients with CLL, MCL, WM, or small B-cell lymphoma treated with zanubrutinib or acalabrutinib. Patients with prior exposure to other BTKis were excluded. After 1:1 propensity score matching, 2887 patients were included in each cohort. We assessed one-year outcomes including new-onset atrial fibrillation/flutter, cerebral infarction, hypertension, and all-cause mortality using Cox proportional hazards modeling. The rate of AF/flutter events observed in the zanubrutinib group (4.05%) was numerically lower compared to the acalabrutinib group (5.25%). Time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time (HR 0.777, 95% CI 0.597-1.012; <i>p</i> = 0.06), which was similar in binary analysis (OR 0.761, 95% CI 0.581-0.997; <i>p</i> = 0.05). Cerebral infarction rates were similar between groups (1.09% vs. 1.12%), with no significant difference in time-to-event analysis (HR 0.984, 95% CI 0.596-1.626; <i>p</i> = 0.95) or binary analysis (<i>p</i> = 0.91). There was no significant difference in onset of hypertension in the zanubrutinib cohort (HR 1.199, 95% CI 0.957-1.501; <i>p</i> = 0.11) All-cause mortality was not statistically significant between the two groups (HR 0.865, 95% CI 0.740-1.012; <i>p</i> = 0.07). In this large, real-world analysis, fewer AF/flutter events were observed with zanubrutinib at one year; however, time-to-event analysis did not demonstrate a statistically significant difference in AF risk over time. Notably, hypertension, cerebral infarction, and all-cause mortality occurred at similar rates. This suggests zanubrutinib and acalabrutinib share similar cardiovascular safety profiles overall. However these findings are hypothesis-generating and require prospective validation before definitive conclusions about cardiovascular risk can be drawn.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-20DOI: 10.3390/curroncol33100633
Matthew Strelau, Gregoire Le Gal, Arleigh McCurdy, Sudeep Shivakumar, Jared C Wootten, Maisam Abouzeenni, Chai W Phua, Selay Lam, Alejandro Lazo-Langner, Mohamed Y Abouzeenni, Martha Louzada
{"title":"Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM).","authors":"Matthew Strelau, Gregoire Le Gal, Arleigh McCurdy, Sudeep Shivakumar, Jared C Wootten, Maisam Abouzeenni, Chai W Phua, Selay Lam, Alejandro Lazo-Langner, Mohamed Y Abouzeenni, Martha Louzada","doi":"10.3390/curroncol33100633","DOIUrl":"10.3390/curroncol33100633","url":null,"abstract":"<p><p>Venous thromboembolism is a serious medical complication with an increased risk in patients with multiple myeloma undergoing combination treatment regimens. Acetylsalicylic acid is routinely used as a method of thromboprophylaxis in multiple myeloma patients treated with lenalidomide, and rivaroxaban has been assessed in small-scale studies in multiple myeloma patients treated with immunomodulatory drugs; yet, no study has compared the two methods. In this pilot, we asked if a full-scale trial would be feasible to assess the benefits of rivaroxaban over acetylsalicylic acid as a thromboprophylactic approach. This pilot recruited patients with multiple myeloma on lenalidomide-based therapy and randomized them to either low-dose acetylsalicylic acid or rivaroxaban, then monitored bleeding and thrombotic events throughout lenalidomide-dexamethasone treatment. A total of 55 patients were recruited across three Canadian centres, with two venous thromboembolic events and two bleeding events, all in the acetylsalicylic acid arm. We conducted a post hoc analysis of active recruitment time as a definition of recruitment feasibility, as we did not achieve our pre-defined feasibility goals. Despite the challenges in enrollment, possibly due to social restrictions during the COVID-19 pandemic, we maintain that a full-scale trial is feasible and offers insight into thromboprophylactic management in this population.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-20DOI: 10.3390/curroncol33100637
Srinivasan Vijayakumar, Marc Matrana, Vani Vijayakumar
{"title":"Integrated Radiobiotherapy: A State-Based Framework for Response-Adaptive Combination Oncology.","authors":"Srinivasan Vijayakumar, Marc Matrana, Vani Vijayakumar","doi":"10.3390/curroncol33100637","DOIUrl":"10.3390/curroncol33100637","url":null,"abstract":"<p><p><b>Background:</b> Cancer care increasingly requires coordinated use of systemic therapy, targeted radionuclide therapy (TRT), and external-beam radiotherapy (EBRT), yet clinical workflows often remain organized around static staging and sequential specialty handoffs. <b>Approach:</b> We propose Integrated Radiobiotherapy (IRBT), a state-based, response-adaptive research framework in which molecular imaging, systemic therapy, TRT, and EBRT can be evaluated as coordinated components of prospective studies. The framework uses shared selection criteria, response measures, and prespecified adaptation options-escalate, consolidate, switch, or de-escalate. The oligometastatic and oligoprogressive spectrum serves as a pragmatic clinical testbed, while two landmark 1995 papers provide historical context for the implementation discipline required. <b>Key Recommendations:</b> Trials should evaluate sequencing at clinically relevant decision points, use state-based endpoints that capture lesion-level control and spatial heterogeneity, establish minimum governance standards with multidisciplinary peer review and cumulative-toxicity safeguards, and address equity, ethics, and resource intensity as core implementation requirements. <b>Conclusions:</b> Although individual components-including oligometastatic stereotactic body radiotherapy, TRT, and adaptive EBRT-have prospective support, the fully integrated response-adaptive strategy remains unvalidated. IRBT offers a proposed structure and research agenda for multimodality oncology trials; it is not a clinical practice guideline or treatment mandate. <i>\"Those who cannot remember the past are condemned to repeat it.\"</i>-George Santayana.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-20DOI: 10.3390/curroncol33100634
Giovanni Ursi, Matea Lekić, Hrvoje Kaučić, Aleksandar Kovačević, Domagoj Kosmina, Karla Schwarz, Dragan Schwarz, Damir Vučinić
{"title":"CBCT-Guided Online Adaptive Ultrahypofractionated Whole-Breast Radiotherapy for Early-Stage Breast Cancer: Dosimetric Outcomes and Acute Toxicity.","authors":"Giovanni Ursi, Matea Lekić, Hrvoje Kaučić, Aleksandar Kovačević, Domagoj Kosmina, Karla Schwarz, Dragan Schwarz, Damir Vučinić","doi":"10.3390/curroncol33100634","DOIUrl":"10.3390/curroncol33100634","url":null,"abstract":"<p><p>Ultrahypofractionated whole-breast radiotherapy reduces treatment burden but increases the importance of accurate dose delivery at each fraction. This retrospective single-center study evaluated cone-beam computed tomography-guided online adaptive radiotherapy in 55 patients with early-stage breast cancer treated with 26 or 27 Gy in five fractions. Dosimetric analysis was available for 52 patients and 259 paired scheduled and adapted fractions. Linear mixed-effects models with a patient-specific random intercept were used to account for repeated fractions within individual patients. The adapted plan was selected for 242 out of 260 delivered fractions (93.1%). Mean planning target volume V95% increased from 93.52 ± 2.94% with the scheduled plan to 98.13 ± 1.04% with adaptation (<i>p</i> < 0.001), with reduced interfraction variability. Ipsilateral lung V30% increased modestly from 13.94% to 14.96% (<i>p</i> < 0.001). In left-sided cases, no significant differences were observed for heart V25% (1.400% vs. 1.395%; <i>p</i> = 0.3825) or left anterior descending coronary artery D0.03 cm<sup>3</sup> (1.771 vs. 1.873 Gy; <i>p</i> = 0.1390). Acute grade 1 toxicity occurred in five patients (9.1%), with no grade ≥ 2 events. Mean treatment-session duration was 28 min. Online adaptation significantly improved daily target coverage and was technically feasible within a five-fraction whole-breast workflow. Acute toxicity was limited in this cohort, while longer follow-up and cumulative dose analyses are needed to further define its impact on organ-at-risk exposure and clinical outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-20DOI: 10.3390/curroncol33100630
John R Goffin, Sze Wah Samuel Chan, Gregory R Pond
{"title":"Frequency of Bloodwork in Patients on Immune Checkpoint Inhibitors.","authors":"John R Goffin, Sze Wah Samuel Chan, Gregory R Pond","doi":"10.3390/curroncol33100630","DOIUrl":"10.3390/curroncol33100630","url":null,"abstract":"<p><p><b>Purpose:</b> Immune checkpoint inhibitors (ICIs) are widely used to treat solid tumours. Prolonged use leads to increased bloodwork to monitor for adverse events (AEs). We explored the safety of decreasing bloodwork frequency while administering an ICI. <b>Methods:</b> Data was collected on patients receiving ICIs without chemotherapy for solid tumours from 2015 to 2020 at an academic cancer centre in Canada. Demographics, cancer diagnosis, ICI use, and pre-treatment bloodwork were extracted. The control group comprised all patients with all detected AEs. We modelled a decreased frequency of bloodwork by assuming that those same patients had bloodwork taken only every second or third cycle. The primary outcome was the proportion of patients with a missed bloodwork-related AE of grade 2 or higher. Descriptive statistics were used. <b>Results:</b> Among 735 patients, median age was 67, 65% were male, and most had lung cancer (39.6%) or melanoma (38.9%). Most (90.5%) received monotherapy. When neutropenia and lymphopenia were excluded, grade 2+ bloodwork-related AEs occurred in 20.9 to 27.7% of patients prior to cycle 2 of the ICI. When bloodwork is omitted every two or three cycles, respective AE miss rates were as high as 5.2 and 8.3% for thyroid abnormalities, 4.6 and 8.1% for hyperglycemia, and 1.6 and 2% for hepatitis. During the first period of bloodwork omission, overall grade 2+ AE miss rates were 10.4 to 12.4% when bloodwork was done every two cycles, and 17.9 to 23.8% when bloodwork was done every three cycles, varying by cycle duration. Miss rates were lower in later cycles. <b>Conclusions:</b> ICI bloodwork-related grade 2+ AE miss rates exceed 10% when bloodwork is omitted, suggesting that bloodwork should be obtained with each cycle of an ICI administered.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current oncologyPub Date : 2026-10-20DOI: 10.3390/curroncol33100631
Berkan Karabuga, Ekin Konca Karabuga, Osman Bilge Kaya
{"title":"Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. <i>Curr. Oncol.</i> 2026, <i>33</i>, 462.","authors":"Berkan Karabuga, Ekin Konca Karabuga, Osman Bilge Kaya","doi":"10.3390/curroncol33100631","DOIUrl":"10.3390/curroncol33100631","url":null,"abstract":"<p><p>Time to treatment failure (TTF) is a pragmatic endpoint that captures treatment discontinuation for multiple reasons. In a recent nationwide C-CAT registry analysis, Kajiura et al. examined whether facility-level medical oncology specialist availability was associated with first-line TTF among patients with lung cancer. We highlight two considerations that may influence the interpretation of facility-level differences in TTF: the heterogeneous reasons underlying treatment termination and the post-first-line selection inherent to C-CAT registration. Examining treatment-ending reasons and the timing of C-CAT registration across specialist-availability groups may help clarify whether differences in TTF reflect treatment duration itself or differences in cohort composition and treatment-discontinuation processes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on \"Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. <i>Curr. Oncol.</i> 2026, <i>33</i>, 462\".","authors":"Shinya Kajiura, Hironaga Satake, Ryuji Hayashi, Takayuki Yoshino","doi":"10.3390/curroncol33100632","DOIUrl":"10.3390/curroncol33100632","url":null,"abstract":"<p><p>We thank Karabuga and Kaya for their Comment on our nationwide C-CAT registry analysis of facility-level medical oncology specialist availability and first-line time to treatment failure (TTF) in lung cancer. We agree that the heterogeneous composition of TTF events and the predominantly post-first-line timing of C-CAT registration are important to interpretation. In this Reply, we clarify that TTF should be interpreted as the duration of a recorded first-line treatment process rather than as a direct measure of progression, treatment efficacy, survival benefit, facility quality, or individual specialist contribution. We also provide group-specific information on endpoint composition and the interval from first-line treatment initiation to C-CAT registration. Because treatment-ending causes were not clinically standardized and registration timing was itself post-treatment and selection-related, we did not perform additional cause-specific or registration-interval-stratified analyses. No new patient-level analysis was performed for this Reply.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}